NESVIZH, 29 July (BelTA) – Chairperson of the Council of the Republic of the National Assembly of Belarus Natalya Kochanova paid a visit to the Belarusian-Dutch joint venture Pharmland in Nesvizh on 28 July, BelTA has learned.
According to the speaker, her visit was organized following the meeting with the specialists of the Transfusiology Center of Minsk Clinical Hospital No. 6 and the National Scientific and Practical Center of Transfusiology and Medical Biotechnologies. Natalya Kochanova noted that plasma-based products is an issue under the constant control of the Belarusian healthcare system.
“I am mostly interested in the possibility of providing our citizens with blood plasma. I would also like to know about the quality of blood products made in our country today,” stressed the chairperson of the Council of the Republic during her visit to the production facility.
“Our production is an import-substituting project, because blood plasma products are brought in from abroad. They can be produced from local raw materials - donor plasma. The technology is absolutely unique, and we are the only plant in Belarus, Russia, and other CIS states that is able to produce a full line of all necessary plasma-based drugs. We are ready to provide 100% import substitution in Belarus, and in some positions to fully satisfy the Russian market,” said Vadim Senchuk, Deputy Director General for Scientific and Innovative Work, Associate Professor of Farmland.
According to him, the company produces vital and important drugs for the treatment of patients, including those with hemophilia, burns, and cancer. Plasma processing capacity is 600,000 liters per year. Plans are in place to expand the lineup of medications, because donor blood plasma contains several dozens of therapeutically valuable proteins.
In 2021 the Belarusian-Dutch joint venture Pharmland produced over 100 items of medications, including solutions for infusions, injections, solid tablet forms of drugs, syrups, suspensions, sprays, powders, eye drops, and also plasma-based products. In 2018, the company launched the production of liquid for inhalation anesthesia. The company also makes 33 items of test systems for the diagnosis of various diseases, three types of cardiac bioprostheses, ten items of concentrates for hemodialysis, eight enteral feeding products, 12 items of dietary supplements, and seven types of cosmetics.
In 2022 the company plans to register about 14 more medications and is also working on the development of more than 50 products. The company sells to Russia, Azerbaijan, Kazakhstan, Uzbekistan, Georgia, Pakistan, and Vietnam.
The construction of a plant to produce blood plasma medications was completed in December 2015. Thus, today Belarus boasts a modern large-scale pharmaceutical production of high-tech protein drugs from blood plasma. The implementation of the project will fully satisfy the need of the country for highly effective and safe blood plasma medications, provide specialized care to patients in accordance with the requirements of modern medicine and advanced standards of drug provision.
The company employs 446 specialists.
